"We anticipate, however, that at some point -- after abuse-deterrent formulations have become available for a number of different opioid active moieties and after we have obtained more experience with this field -- FDA will determine that the risks of all or most opioid products that lack abuse-deterrent properties outweigh the benefits in light of available therapies."
Market Data 
Markets 
AI
